The Latest Cardiac and Vascular News
SILVER SPRING, Md., Feb. 24, 2022 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults. Jardiance was originally approved by the FDA in 2014 as a supplement to diet and exercise to improve glucose control […]
Exceeded 2021 financial guidance with revenues of more than $800 million Webcast today, February 24, 2022, at 11:30 a.m. Eastern Time CARLSBAD, Calif., Feb. 24, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the fourth quarter and full year ended December 31, 2021, and recent business achievements. “During 2021, we […]
Extensive analysis for U.S. by MedStar Health Research Institute determined icosapent ethyl is cost-effective compared to standard of care, both during the REDUCE-IT® clinical trial period and over a lifetime projection BRIDGEWATER, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) — JAMA Network Open has published “Cost-effectiveness of Icosapent Ethyl for High-risk Patients With […]
SAN FRANCISCO, Feb. 23, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today reported financial results for the three months and full year ended December 31, 2021. Fourth Quarter 2021 Financial Highlights Revenue of $81.8 million, […]
CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today provides a summary of corporate accomplishments and reports its fourth quarter and full year 2021 financial results. Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, […]
– Topline data expected in the first half of 2023 PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES-2 clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as […]
Double-digit percentage revenue and patient count growth in full-year 2021 Company reaffirms target to reach 6,000 patients with Tyvaso by the end of 2022 Major amendment to Tyvaso DPI™ NDA pushes FDA decision date to May 2022 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), […]
First AI-powered cerebral aneurysm detection solution designed to facilitate population screening and enhanced care management SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the world leader in artificial intelligence (AI) powered care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Viz ANEURYSM. The new algorithm uses AI to […]
– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout February 23, 2022 04:05 PM Eastern Standard Time PARK CITY, Utah–(BUSINESS WIRE)–Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2021. For the fourth quarter of 2021, worldwide sales from continuing operations were $270.1 million, an increase of 0.2 percent on a reported basis and 1.8 […]
